Review top news and interview highlights from the week ending August 16, 2024.
CGTLive®’s Weekly Rewind
Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
Despite approval by the FDA on December 8, 2023, only 4 patients have begun treatment with lovo-cel in the commercial setting.
The president and chief executive officer of Passage Bio discussed feedback from a recent Type C meeting with the FDA.
In light of the FDA’s decision, 4DMT plans to continue enrolling patients in INGLAXA before the end of 2024.
The head of therapeutics at Epic Bio discussed EPI-321, an investigational treatment for facioscapulohumeral muscular dystrophy.
The company reported promising early efficacy data from the Acclaim-1 and Acclaim-3 trials, but has discontinued Acclaim-2, citing difficulty enrolling patients.